Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:596503.
doi: 10.1155/2014/596503. Epub 2014 Apr 30.

Biomarkers Predict Relapse in Granulomatosis with Polyangiitis

Affiliations

Biomarkers Predict Relapse in Granulomatosis with Polyangiitis

Patrick C P Hogan et al. J Biomark. 2014.

Abstract

Granulomatosis with polyangiitis (GPA) is a small blood vessel vasculitic disorder with a high mortality rate if undiagnosed or treated inadequately. Disease relapse is a key feature of this disease and early identification of relapse episodes is very important in limiting end-organ damage. The advent of indirect immunofluorescence to detect antineutrophil cytoplasmic antibody (ANCA) with specific reactivity against the enzyme proteinase-3 (PR3) has been very useful in the diagnosis of GPA but is less helpful in predicting relapse. Indeed, up to date no satisfactory biomarker has been identified that can reliably predict relapse. This study assessed the probability of the occurrence of a relapse when a change was noted in a range of commonly used laboratory tests. These tests included levels of C-reactive protein (CRP), anti-PR3 antibodies, ANCA titre, and the neutrophil count. A group of 30 GPA patients with a total of 66 relapse episodes was investigated and a novel clinical yield score was devised. When a combined rise in CRP, anti-PR3 antibodies, and neutrophil count was observed in the 6-month period before a relapse event, 59% of patient relapses could be predicted. Monitoring changes in this set of parameters helps identify disease relapse.

PubMed Disclaimer

Similar articles

Cited by

References

    1. van der Woude F. J., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. The Lancet. 1985;1(8426):425–429. - PubMed
    1. Jennette J. C., Hoidal J. R., Falk R. J. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood. 1990;75(11):2263–2264. - PubMed
    1. Koldingsnes W., Nossent H. Predictors of survival and organ damage in Wegener’s granulomatosis. Rheumatology. 2002;41(5):572–581. - PubMed
    1. Despujol C. P.-D., Pouchot J., Pagnoux C., Coste J., Guillevin L. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology. 2010;49(11):2181–2190. doi: 10.1093/rheumatology/keq244.keq244 - DOI - PubMed
    1. Pagnoux C., Hogan S. L., Chin H., et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody—associated small-vessel vasculitis. Arthritis and Rheumatism. 2008;58(9):2908–2918. doi: 10.1002/art.23800. - DOI - PMC - PubMed

LinkOut - more resources